Neel D Trivedi1, Samantha Armstrong1, Hongkun Wang1, Marion Hartley2, John Deeken3, A Ruth He1, Deepa Subramaniam1, Heather Melville1, Chris Albanese1, John L Marshall1, Jimmy Hwang4, Michael J Pishvaian5. 1. Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA. 2. The Ruesch Center for the Cure of Gastrointestinal Cancers, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA. 3. Inova Schar Cancer Institute, Inova Health System, Falls Church, VA, USA. 4. Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC, USA. 5. Department of Oncology, Johns Hopkins University School of Medicine, SKCC, Washington, DC, USA.
Abstract
BACKGROUND: Temsirolimus is an mTOR antagonist with proven anticancer efficacy. Preclinical data suggest greater anticancer effect when mTOR inhibitors are combined with cytotoxic chemotherapy. We performed a Phase I assessment of the combination of temsirolimus and capecitabine in patients with advanced solid tumors. METHODS: Patients were enrolled in an alternating dose escalation of temsirolimus (at 15 or 25 mg IV weekly) and capecitabine (at 750, 1000, and 1250 mg/m2 twice daily) in separate Q2-week and Q3-week cohorts. At the recommended Phase II doses (RP2Ds) of temsirolimus and capecitabine (Q2), seven patients were also treated with oxaliplatin (85 mg/m2 , day 1) to determine triplet combination safety and efficacy. RESULTS: Forty-five patients were enrolled and 41 were evaluable for dose-limiting toxicities (DLTs). The most common adverse events (AEs) were mucositis, fatigue, and thrombocytopenia. The most common grade 3/4 AEs were hypophosphatemia and anemia. Five patients had DLTs, including hypophosphatemia, mucositis, and thrombocytopenia. The RP2Ds were temsirolimus 25 mg +capecitabine 1000 mg/m2 (Q2); and temsirolimus 25 mg +capecitabine 750 mg/m2 (Q3). Of the 38 patients evaluable for response, one had a partial response (PR) and 19 had stable disease (SD). The overall disease control rate was 52%. Five of the 20 patients with SD/PR maintained disease control for >6 months. CONCLUSIONS: The combination of temsirolimus and capecitabine is safe on both a Q2-week and a Q3-week schedule. The combination demonstrated promising evidence of disease control in this highly refractory population and could be considered for testing in disease-specific phase II trials.
BACKGROUND:Temsirolimus is an mTOR antagonist with proven anticancer efficacy. Preclinical data suggest greater anticancer effect when mTOR inhibitors are combined with cytotoxic chemotherapy. We performed a Phase I assessment of the combination of temsirolimus and capecitabine in patients with advanced solid tumors. METHODS:Patients were enrolled in an alternating dose escalation of temsirolimus (at 15 or 25 mg IV weekly) and capecitabine (at 750, 1000, and 1250 mg/m2 twice daily) in separate Q2-week and Q3-week cohorts. At the recommended Phase II doses (RP2Ds) of temsirolimus and capecitabine (Q2), seven patients were also treated with oxaliplatin (85 mg/m2 , day 1) to determine triplet combination safety and efficacy. RESULTS: Forty-five patients were enrolled and 41 were evaluable for dose-limiting toxicities (DLTs). The most common adverse events (AEs) were mucositis, fatigue, and thrombocytopenia. The most common grade 3/4 AEs were hypophosphatemia and anemia. Five patients had DLTs, including hypophosphatemia, mucositis, and thrombocytopenia. The RP2Ds were temsirolimus 25 mg +capecitabine 1000 mg/m2 (Q2); and temsirolimus 25 mg +capecitabine 750 mg/m2 (Q3). Of the 38 patients evaluable for response, one had a partial response (PR) and 19 had stable disease (SD). The overall disease control rate was 52%. Five of the 20 patients with SD/PR maintained disease control for >6 months. CONCLUSIONS: The combination of temsirolimus and capecitabine is safe on both a Q2-week and a Q3-week schedule. The combination demonstrated promising evidence of disease control in this highly refractory population and could be considered for testing in disease-specific phase II trials.
Authors: Stephen Chan; Max E Scheulen; Stephen Johnston; Klaus Mross; Fatima Cardoso; Christian Dittrich; Wolfgang Eiermann; Dagmar Hess; Rudolph Morant; Vladimir Semiglazov; Markus Borner; Marc Salzberg; Valerijus Ostapenko; Hans-Joachim Illiger; Dirk Behringer; Nathalie Bardy-Bouxin; Joseph Boni; Steven Kong; Maria Cincotta; Laurence Moore Journal: J Clin Oncol Date: 2005-06-13 Impact factor: 44.544
Authors: Elizabeth Buck; Alexandra Eyzaguirre; John D Haley; Neil W Gibson; Pablo Cagnoni; Kenneth K Iwata Journal: Mol Cancer Ther Date: 2006-08 Impact factor: 6.261
Authors: Sven A Lang; Andreas Gaumann; Gudrun E Koehl; Ulrike Seidel; Frauke Bataille; Dagmar Klein; Lee M Ellis; Ulrich Bolder; Ferdinand Hofstaedter; Hans-Jürgen Schlitt; Edward K Geissler; Oliver Stoeltzing Journal: Int J Cancer Date: 2007-04-15 Impact factor: 7.396
Authors: Autumn J McRee; Janine M Davies; Hanna G Sanoff; Richard M Goldberg; Stephen Bernard; E Claire Dees; Kimberly Keller; Anastasia Ivanova; Bert H O'Neil Journal: Cancer Chemother Pharmacol Date: 2014-05-13 Impact factor: 3.333
Authors: Patrick Frost; Farhad Moatamed; Bao Hoang; Yijiang Shi; Joseph Gera; Huajun Yan; Philip Frost; Jay Gibbons; Alan Lichtenstein Journal: Blood Date: 2004-08-10 Impact factor: 22.113
Authors: S C Oh; H Y Sur; H J Sung; I K Choi; S S Park; J H Seo; Y T Jeen; H J Chun; S W Shin; Y J Mok; J S Kim; Y H Kim Journal: Br J Cancer Date: 2007-05-01 Impact factor: 7.640